--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About MBX20260220C35
Pharmaceutical
MBX Biosciences, Inc., was incorporated in Indiana in August 2018 and transformed into a Delaware corporation in April 2019. They are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic diseases. Founded by global leaders, their companies take a transformative approach to the design and development of peptide medicines. Using this expertise, they designed their proprietary Precision Endocrine Peptide (PEPTM) platform to overcome the key limitations of unmodified and modified peptide therapy, improve clinical outcomes and simplify disease management for patients.
